BioCryst Pharmaceuticals, Inc. $BCRX Shares Sold by Fisher Asset Management LLC

Key Points

• Fisher Asset Management trimmed its stake in BioCryst by 5.4%, selling 149,793 shares and ending the quarter with 2,632,696 shares (~1.25% of the company) valued at about $19.98 million.
• BioCryst reported a strong quarter, posting EPS of $1.12 versus a $0.07 estimate and revenue of $163.3 million (up 209% year-over-year), with a reported net margin of 30.16%.
• Analyst sentiment is mixed but overall positive: the consensus rating is "Moderate Buy" with an average target of $19.64, while individual price targets range roughly from $13 to $32.

Fisher Asset Management LLC cut its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 5.4% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,632,696 shares of the biotechnology company's stock after selling 149,793 shares during the period. Fisher Asset Management LLC owned about 1.25% of BioCryst Pharmaceuticals worth $19,982,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the stock. Farther Finance Advisors LLC raised its position in BioCryst Pharmaceuticals by 326.8% in the 3rd quarter. Farther Finance Advisors LLC now owns 10,590 shares of the biotechnology company's stock valued at $80,000 after purchasing an additional 8,109 shares in the last quarter. Vestmark Advisory Solutions Inc. purchased a new stake in shares of BioCryst Pharmaceuticals during the third quarter worth approximately $81,000. State of Alaska Department of Revenue acquired a new stake in BioCryst Pharmaceuticals in the third quarter valued at approximately $90,000. Inceptionr LLC purchased a new position in BioCryst Pharmaceuticals in the second quarter worth approximately $107,000. Finally, MQS Management LLC purchased a new position in BioCryst Pharmaceuticals in the third quarter worth approximately $99,000. Hedge funds and other institutional investors own 85.88% of the company's stock.

Analysts Set New Price Targets

Several research analysts have commented on the stock. Royal Bank Of Canada lowered their price target on shares of BioCryst Pharmaceuticals from $14.00 to $13.00 and set an "outperform" rating for the company in a report on Friday, January 30th. Weiss Ratings reissued a "sell (e+)" rating on shares of BioCryst Pharmaceuticals in a report on Monday, December 29th. HC Wainwright increased their target price on BioCryst Pharmaceuticals from $30.00 to $32.00 and gave the company a "buy" rating in a report on Monday, December 15th. Evercore started coverage on BioCryst Pharmaceuticals in a report on Wednesday, February 18th. They set an "outperform" rating and a $17.00 price target for the company. Finally, Citizens Jmp lowered their price objective on BioCryst Pharmaceuticals from $27.00 to $25.00 and set a "market outperform" rating for the company in a research report on Wednesday, November 5th. Ten equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $19.64.

BioCryst Pharmaceuticals Price Performance

Shares of BCRX opened at $8.57 on Thursday. BioCryst Pharmaceuticals, Inc. has a 1-year low of $6.00 and a 1-year high of $11.31. The stock has a market cap of $2.15 billion, a PE ratio of 7.14 and a beta of 0.74. The firm has a fifty day moving average price of $7.20 and a 200 day moving average price of $7.40.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last issued its quarterly earnings data on Thursday, February 26th. The biotechnology company reported $1.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.07 by $1.05. BioCryst Pharmaceuticals had a negative return on equity of 84.33% and a net margin of 30.16%.The company had revenue of $163.28 million for the quarter, compared to analyst estimates of $151.32 million. During the same quarter last year, the company posted ($0.13) earnings per share. The business's quarterly revenue was up 209.1% compared to the same quarter last year. As a group, equities analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current fiscal year.

Insider Transactions at BioCryst Pharmaceuticals

In other BioCryst Pharmaceuticals news, insider Alane P. Barnes sold 21,773 shares of BioCryst Pharmaceuticals stock in a transaction that occurred on Monday, December 22nd. The stock was sold at an average price of $7.65, for a total transaction of $166,563.45. Following the transaction, the insider owned 398,751 shares of the company's stock, valued at $3,050,445.15. The trade was a 5.18% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 5.10% of the stock is owned by corporate insiders.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company's first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.

Want to see what other hedge funds are holding BCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.